Treatment of hypertensive patients in community pharmacies in Yogyakarta
Keywords:
Hypertensive, Prescribing pattern, Community pharmaciesAbstract
Hypertension is one of the degenerative diseases that has quite high mortality and morbidity. Rational drug management in hypertensive patients has become an increasingly important topic to make optimal use of the treatment to provide the highest possible standard of health care. Continuous assessment of rational drug prescription and use should be carried out in patients. The purpose of this study is to identify the trend of drug prescription and using antihypertensive groups in hypertensive patients in community pharmacies in Yogyakarta in 2024. This study aimed to conduct a retrospective cross-sectional study of prescription patterns in hypertensive patients in the community. The review of drug prescription characteristics includes gender, age, comorbidities, duration of treatment, and number of drugs used. The results showed that 56.06% of hypertensive patients were male patients, the dominant age in this study was over 60 years (59.09%). The duration of treatment in this study was dominated by 5-10 days (79.55%). Hypertensive patients usually have 1-3 comorbidities so that be will affect the treatment received. As many as 84.85% of hypertensive patients use a single hypertension drug. Amlodipine is a CCB group that is the first line of hypertension treatment in the community. The combination of treatments that often used is a combination of the CCB group (amlodipine) with the diuretic group (furosemide).
References
[1] NHLBI, “High Blood Pressure - What Is High Blood Pressure?” Accessed: Dec. 08, 2024. [Online]. Available: https://www.nhlbi.nih.gov/health/high-blood-pressure
[2] R. Rahmawati and B. V. Bajorek, “Access to medicines for hypertension: a survey in rural Yogyakarta province, Indonesia,” Rural and Remote Health, vol. 18, no. 3, Aug. 2018, doi: 10.22605/RRH4393.
[3] M. R. Wati, M. Mustofa, and I. P. Sari, “The Effect Of Community Pharmacist’s Counseling On Hypertensive Patients,” Jurnal Manajemen Dan Pelayanan Farmasi (Journal of Management and Pharmacy Practice), vol. 5, no. 1, Art. no. 1, Mar. 2015, doi: 10.22146/jmpf.28.
[4] M. A. F. Alfana, A. J. Pitoyo, U. Listyaningsih, Y. Yaseva, and M. Yushafira, “Distribusi dan Karakteristik Penderita Hipertensi di Daerah Istimewa Yogyakarta,” MGI, vol. 38, no. 1, Feb. 2024, doi: 10.22146/mgi.84531.
[5] S. Pobas, B. Nazaruddin, S. Palutturi, W. Wahiduddin, S. S. Russeng, and A. Mallongi, “Policy Implementation of Hypertension Prevention and Control Program in Banjarmasin,” Pharmacogn J., vol. 15, no. 4, pp. 641–649, Aug. 2023, doi: 10.5530/pj.2023.15.132.
[6] M. Al Ahmad, R. Beiram, and S. AbuRuz, “Application of the American College of Cardiology (ACC/AHA) 2017 Guideline for the Management of Hypertension in Adults and Comparison with the 2014 Eighth Joint National Committee Guideline,” J Saudi Heart Assoc, vol. 33, no. 1, pp. 16–25, Apr. 2021, doi: 10.37616/2212-5043.1233.
[7] C. Armstrong, “JNC 8 Guidelines for the Management of Hypertension in Adults,” afp, vol. 90, no. 7, pp. 503–504, Oct. 2014.
[8] A. F. Nilansari, N. M. Yasin, and D. A. Puspandari, “Gambaran Pola Penggunaan Obat Antihipertensi Pada Pasien Rawat Inap di RSUD Panembahan Senopati,” Lumbung Farmasi: Jurnal Ilmu Kefarmasian, vol. 1, no. 2, pp. 73–79, Jul. 2020, doi: 10.31764/lf.v1i2.2577.
[9] M. Heisler et al., “Improving blood pressure control through a clinical pharmacist outreach program in patients with diabetes mellitus in 2 high-performing health systems: the adherence and intensification of medications cluster randomized, controlled pragmatic trial,” Circulation, vol. 125, no. 23, pp. 2863–2872, Jun. 2012, doi: 10.1161/CIRCULATIONAHA.111.089169.
[10] B. Williams, “The Year in Hypertension | Journal of the American College of Cardiology,” Journal of the American Collage Cardiology, vol. 51, no. 18, pp. 1803–1817, May 2008.
[11] Z. G. Saputri, A. Akrom, and E. Darmawan, “Tingkat Kepatuhan Antihipertensi Dan Pengontrolan Tekanan Darah Pasien Rawat Jalan Rs Pku Muhammadiyah Bantul, Yogyakarta Yang Mendapatkan Brief Counseling-5A Dan SMS Motivasional,” Jurnal Farmasi Sains dan Komunitas (Journal of Pharmaceutical Sciences and Community), vol. 13, no. 2, Art. no. 2, Nov. 2016, doi: 10.24071/jpsc.00189.
[12] A. Sari, F. Baroroh, and F. P. Astuti, “The relationship between drug therapy adherence and the results of blood pressure targets achievement in hypertensive patients with dyslipidemia complications at Government Hospital in Yogyakarta,” Pharmaciana, vol. 10, no. 3, Art. no. 3, Oct. 2020, doi: 10.12928/pharmaciana.v10i3.16553.
[13] WHO, “Promoting rational use of medicines.” Accessed: Dec. 08, 2024. [Online]. Available: https://www.who.int/activities/promoting-rational-use-of-medicines
[14] P. J. Connelly, G. Currie, and C. Delles, “Sex Differences in the Prevalence, Outcomes and Management of Hypertension,” Curr Hypertens Rep, vol. 24, no. 6, pp. 185–192, Jun. 2022, doi: 10.1007/s11906-022-01183-8.
[15] B. Everett and A. Zajacova, “Gender Differences in Hypertension and Hypertension Awareness Among Young Adults,” Biodemography Soc Biol, vol. 61, no. 1, pp. 1–17, 2015, doi: 10.1080/19485565.2014.929488.
[16] A. Santosa et al., “Gender differences and determinants of prevalence, awareness, treatment and control of hypertension among adults in China and Sweden,” BMC Public Health, vol. 20, no. 1, p. 1763, Nov. 2020, doi: 10.1186/s12889-020-09862-4.
[17] F. Zhou et al., “Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study,” The Lancet, vol. 395, no. 10229, Art. no. 10229, Mar. 2020, doi: 10.1016/S0140-6736(20)30566-3.
[18] W.-J. Yeo et al., “Sex Differences in Hypertension and Its Management Throughout Life,” Hypertension, vol. 81, no. 11, pp. 2263–2274, Nov. 2024, doi: 10.1161/HYPERTENSIONAHA.124.22980.
[19] P. Mohanty, L. Patnaik, G. Nayak, and A. Dutta, “Gender difference in prevalence of hypertension among Indians across various age-groups: a report from multiple nationally representative samples,” BMC Public Health, vol. 22, no. 1, p. 1524, Aug. 2022, doi: 10.1186/s12889-022-13949-5.
[20] W. Cheng et al., “Age-related changes in the risk of high blood pressure,” Front Cardiovasc Med, vol. 9, p. 939103, Sep. 2022, doi: 10.3389/fcvm.2022.939103.
[21] J. Xiong et al., “Age‐specific differences in hypertension combination management and associated factors influencing treatment choice,” J Clin Hypertens (Greenwich), vol. 25, no. 6, pp. 545–554, May 2023, doi: 10.1111/jch.14668.
[22] A. Mannan et al., “Association between comorbidity and health-related quality of life in a hypertensive population: a hospital-based study in Bangladesh,” BMC Public Health, vol. 22, p. 181, Jan. 2022, doi: 10.1186/s12889-022-12562-w.
[23] N. A. Simatupang, V. Widyaningsih, Faculty of Medicine, Universitas Sebelas Maret, S. Sumardiyono, and Faculty of Medicine, Universitas Sebelas Maret, “A Meta-Analysis: Correlation between Hypertension of Comorbidity on Mortality in Patients with COVID-19,” J EPIDEMIOL PUBLIC HEALTH, vol. 6, no. 1, pp. 60–69, 2021, doi: 10.26911/jepublichealth.2021.06.01.07.
[24] D. Hastuti, “Profil Peresepan Obat Antihipertensi Pada Pasien Hipertensi di Apotek Afina,” Majalah Farmaseutik, vol. 18, no. 3, Art. no. 3, Oct. 2022, doi: 10.22146/farmaseutik.v18i3.77737.
[25] T. S. Tutoli, N. Rasdiana, and F. Tahala, “Pola Penggunaan Obat Antihipertensi Pada Pasien Hipertensi,” IJPE, vol. 1, no. 3, pp. 127–135, Sep. 2021, doi: 10.37311/ijpe.v1i3.11083.
Downloads
Published
Conference Proceedings Volume
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.